Sign inJoin waitlistJoin the waitlist

Julius Strauss

Hospitalist

Credentials: · ·

History

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2013–2016
Internal Medicine
2011–2014
Renaissance School of Medicine at Stony Brook University
2006–2010

Research

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Clinical Cancer Research · 2018 · First of 15 authors · 360 citations
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer · 2019 · 238 citations
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Review · Journal for ImmunoTherapy of Cancer · 2020 · 230 citations

James Gulley
34 papers
Ravi Madan
18 papers
Jason Redman
17 papers · 2 as a fellow
Margaret Gatti-Mays
11 papers
Marijo Bilusic
11 papers
Fatima Karzai
10 papers
CH
Christopher Heery
8 papers
IB
Isaac Brownell
7 papers
Charalampos Floudas
6 papers · 2 as a fellow
William Figg
6 papers
DP
Danielle Pastor
4 papers
Houssein Sater
4 papers

Grants

Cancer Immunotherapy Clinical Trials
National Cancer Institute · ZIA
Contact PI · $6M · Division of Basic Sciences - Nci

Clinical trials

M7824 in Subjects With HPV Associated Malignancies
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2018–2022
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2018–2020
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2017–2021